LYEL:NASDAQLyell Immunopharma, Inc. analysis
Data as of Sep 5, 2026 - not real-time
- Latest price
- $14.37
- Risk: high
- 9/10High risk
Summary
Lyell Immunopharma, Inc. is priced at $14.37, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has gained 13.8%. With RSI at 49.3 the momentum picture is neutral, alongside a bearish MACD signal. Recent trading has carved out support near $13.39 and resistance around $17.15.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 163.6% above the current quote. Revenue is contracting at 50.0%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 69.4%, a beta of 1.72 and a maximum drawdown of 69.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 163.6% above the current quote. Revenue is contracting at 50.0%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 69.4%, a beta of 1.72 and a maximum drawdown of 69.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
Top market events
- PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in...
- SOUTH SAN FRANCISCO, Calif. AP — SOUTH SAN FRANCISCO, Calif. AP — Lyell Immunopharma Inc. LYEL on Thursday reported...
- The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting...
Market outlook
Short term
< 1 yearNeutral
Model confidence2/102 out of 10
Key factors
- Trading below the 200-day average of 20.30
- MACD momentum is negative
- 30-day price change of +13.8%
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Trading below the 200-day average of 20.30
- Analyst targets imply +163.6% versus the current price
- 30-day volatility of 69.4%
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +163.6% versus the current price
- Negative return on equity of -93.3%
- Revenue contracting at -50.0%
Key metrics
Financial health
Revenue Growth-50.00%
P/E Ratio-2.3
ROE-93.28%
ROA-34.18%
Debt/Equity19.93
P/B Ratio1.4
Op. Cash Flow$-133260000
Free Cash Flow$-72809128
Industry P/E30.6
Technical analysis
TrendNeutral
RSI49.3
Support$13.39
Resistance$17.15
MA 20$14.69
MA 50$14.05
MA 200$20.30
MACDBearish
VolumeDecreasing
Fear & Greed Index95.48
Valuation
Target Price$37.88
Upside/Downside163.57%
GradeFair
TypeBlend
Risk assessment
Beta1.72
Volatility69.45%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.